<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320582">
  <stage>Registered</stage>
  <submitdate>17/11/2009</submitdate>
  <approvaldate>31/03/2006</approvaldate>
  <actrnumber>ACTRN12609000996268</actrnumber>
  <trial_identification>
    <studytitle>Randomized prospective trial of cyclosporine with/without low-dose prednisolone in idiopathic membranous nephropathy in adults with nephrotic syndrome</studytitle>
    <scientifictitle>Randomized prospective trial of cyclosporine with/without low-dose prednisolone in idiopathic membranous nephropathy in adults with nephrotic syndrome</scientifictitle>
    <utrn />
    <trialacronym>CYPMEN (CYclosporine with/without Prednisolone in MEmbranous Nephropathy) study</trialacronym>
    <secondaryid>Cochrane Renal Group-CRG030600062</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>idiopathic membranous nephropathy with nephrotic syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral administration of cyclosporine 3 mg/kg/day and prednisolone 15 mg/day, for a total of 24 months</interventions>
    <comparator>Oral administration of cyclosporine 3 mg/kg/day. for a total of 24 months</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rates of patients with complete remission or partial remission, and rates of patients with relapse or recurrence by urinaly examinations at the follow-up clinic visiting</outcome>
      <timepoint>24 months after the initiation of the treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>excretion of urinary protein (g/day)</outcome>
      <timepoint>until 24 months after the initiation of the treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum levels of protein and albumin (mg/dL)</outcome>
      <timepoint>until 24 months after the initiation of the treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>creatinine clearance (mL/min)</outcome>
      <timepoint>until 24 months after the initiation of the treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum creatinine level (mg/dL)</outcome>
      <timepoint>until 24 months after the initiation of the treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>adverse effects, such as liver injury, deterioration of renal function, and abnormalities of peripheral blood cell counts by questionnaries and medical examinations</outcome>
      <timepoint>until 24 months after the initiation of the treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Biopsy proven idiopathic membranous nephropathy.

Over 3.5 g/day of excretion of urinary protein.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Secondary forms of membranous nephropathy.
Less than 70 ml/min of creatinine clearance.
Patients with relapse or recurrence.
Treated with other immunosuppressants.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Research Group for Treatments of Kidney Diseases in Ibaraki, Japan</primarysponsorname>
    <primarysponsoraddress>Research Group for Treatments of Kidney Diseases in Ibaraki, University of Tsukuba, 1-1-1 Ten-nodai, Tsukuba, Ibaraki 305-8575</primarysponsoraddress>
    <primarysponsorcountry>Japan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Research Group for Treatments of Kidney Diseases in Ibaraki, Japan</fundingname>
      <fundingaddress>Research Group for Treatments of Kidney Diseases in Ibaraki, University of Tsukuba, 1-1-1 Ten-nodai, Tsukuba, Ibaraki 305-8575</fundingaddress>
      <fundingcountry>Japan</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite>none</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of Tokyo Medical Univsersity Ibaraki Medical Center</ethicname>
      <ethicaddress>3-20-1 Chuo, Ami, Ibaraki 300-0395</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Japan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr, Akio, Koyama</name>
      <address>President, , Ibaraki Prefectural University of Health Science, 4669-2 Ami, Ami, Inashiki, Ibaraki 300-0394</address>
      <phone>+81 29 888 4000</phone>
      <fax />
      <email>koyama@ipu.ac.jp</email>
      <country>Japan</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Kouichi, Hirayama</name>
      <address>Associate professor, Department of Nephrology, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami, Inashiki, Ibaraki 300-0395</address>
      <phone>+81 29 887 1161</phone>
      <fax>+81 29 887 6266</fax>
      <email>k-hira@tokyo-med.ac.jp</email>
      <country>Japan</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Kouichi, Hirayama</name>
      <address>Associate professor, Department of Nephrology, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami, Inashiki, Ibaraki 300-0395</address>
      <phone>+81 29 887 1161</phone>
      <fax>+81 29 887 6266</fax>
      <email>k-hira@tokyo-med.ac.jp</email>
      <country>Japan</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>